Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest gabapentin Stories

2014-04-14 12:33:34

NEWARK, Calif., April 14, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise(®) (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on...

2014-03-10 16:33:25

NEWARK, Calif., March 10, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release fourth quarter fiscal year 2013 financial results after the market closes on Wednesday, March 12, 2014. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm Pacific time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available...

2014-01-29 08:29:54

NEWARK, Calif., Jan. 29, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today a favorable "Markman" claim construction ruling by Judge Joel A. Pisano of the United States District Court for the District of New Jersey in Depomed's ongoing patent infringement case against filers of three Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of Depomed's GRALISE(®) (gabapentin) product prior to the expiration of Depomed's patents listed for Gralise in...

Neuroscience Study Reveals New Player In Obesity
2014-01-08 08:24:33

Tufts University, Health Sciences Campus A protein directs appetite suppressor in the brain; implications for obesity treatment A new neuroscience study sheds light on the biological underpinnings of obesity. The in vivo study, published in the January 8 issue of the Journal of Neuroscience, reveals how a protein in the brain helps regulate food intake and body weight. The findings reveal a potential new avenue for the treatment of obesity and may help explain why medications that are...

2014-01-06 10:16:35

Gabapentin is a gamma-aminobutyric acid derivative, and was approved for the treatment of neuropathic pain by the U.S. Food and Drug Administration in 2002. However, little evidence is available on the effects and me-chanisms of action of gabapentin during the migraine attack period. A recent study by Yanbo Zhang and colleague from Xuanwu Hospital, Capital Medical University in China showed that excitatory amino acids and protein kinase C are involved in the formation and maintenance of...

2013-12-02 08:31:05

NEWARK, Calif., Dec. 2, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Piper Jaffray 25(th) Annual Healthcare Conference at The New York Palace Hotel in New York City. The presentation at the Piper conference is scheduled for 12:10 pm EST (9:10 am PST) on Tuesday, December 3, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A...

2013-11-04 16:29:43

LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ -- The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute (TSRI). "Gabapentin's effect on drinking outcomes is at least as large or greater than those of existing...

2013-10-25 08:25:01

NEWARK, Calif., Oct. 25, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release third quarter fiscal year 2013 financial results after the market closes on Tuesday, November 5, 2013. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via...

2013-08-01 16:31:42

NEWARK, Calif., Aug. 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second quarter fiscal year 2013 financial results after the market closes on Wednesday, August 7, 2013. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

2013-07-03 12:24:23

NEWARK, Calif., July 3, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities Healthcare Conference at the St. Regis Hotel in New York City. The presentation at the JMP conference is scheduled for 11:30 am EDT (8:30 am PDT) on Tuesday, July 9, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...